Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChesnara Regulatory News (CSN)

Share Price Information for Chesnara (CSN)

Share Price is delayed by 15 minutes
Get Live Data
317.50    0.50 (0.16%)
Bid:
315.50
Ask:
317.00
Spread: 1.50 (0.475%)
Market Cap: £732.37m
CSN Live PriceLast checked at - London Stock Exchange

Intraday Chesnara Share Chart

Director/PDMR Shareholding

24 Apr 2025 07:00

RNS Number : 9401F
Chesnara PLC
24 April 2025
Β 

Β 

Β 

LEI Number: 213800VFRMBRTSZ3SJ06

Β 

Β 

24th April 2025

Β 

CHESNARA plc

("Chesnara", "the Company" or the "Group")

Β 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS / PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY ('PDMRs')

Β 

Chesnara plc (CSN.L) announces that on 22nd April 2025, newly appointed Group General Counsel and PDMR Emma Dawe was granted an award over the ordinary shares of the Company under the Chesnara plc 2023 Long Term Incentive Plan. This award was made in accordance with the Directors' Remuneration Policy which was approved by shareholders on 16th May 2023.

Β 

Emma is a member of the Group Senior Leadership Team and joins Chesnara with over a decade of experience advising private and listed Financial Services clients on strategic activity including M&A working for leading Global law firms Pinsent Masons and, recently in a development role, at Kirkland & Ellis International LLP.

Β 

The notification for PDMR is being made in accordance with the requirements of the UK Market Abuse Regulations and provides further detail of the award granted.

Β 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

b)

Natural person:

Legal person

Emma Dawe

2

Reason for the notification

a)

Position/status:

Group General Counsel

b)

Initial notification/amendment

Initial notification

3

Details of the Issuer

a)

Name

Chesnara plc

b)

Legal Entity Identifier:

213800VFRMBRTSZ3SJ06

4

Details of the transaction(s): Parts a-d of this section are to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.

a)

Description of the financial instrument, type of instrument (Identification code)

Chesnara plc Ordinary Shares of 5 pence each

(GB00B00FPT80)

b)

Nature of the transaction

Granted under the Chesnara 2023 Long Term Incentive Plan, the option is subject to performance targets over a period of three financial years.

Β 

Subject to the achievement of the performance target, the option will become exercisable on 22nd April 2028 and remain exercisable up to and including 22nd April 2035 if not exercised before that date.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

37,109 Ordinary shares of 5p each

d)

Aggregated information

- Aggregated volume

- Price

Β 

- 37,109 ORDINARY SHARES OF 5P EACH

- Nil

e)

Date of the transaction (YYYY - MM - DD)

2025-04-22

f)

Place of the transaction

XOFF

Β 

Β 

Name of authorised official of issuer responsible for making notification: -

Al Lonie, Group Chief of Staff & Company Secretary

Β 

Date of notification: - 24th April 2025

Β 

Β 

The above notification is made in accordance with the requirements of the UK Market Abuse Regulation.

Β 

For further information, please contact:

Β 

Investor Enquiries

Sam Perowne

Head of Strategic Development & Investor Relations

Chesnara plc

E - sam.perowne@chesnara.co.uk

Β 

Media Enquiries

Misha Bayliss - +44 20 7427 5465

Oscar Burnett - +44 20 7427 5435

Teneo

E - chesnara@teneo.com

Β 

Β 

Notes to Editors

Chesnara (CSN.L) is a European life and pensions consolidator listed on the London Stock Exchange. It administers just under one million policies and operates as Countrywide Assured in the UK, as The Waard Group and Scildon in the Netherlands and as Movestic in Sweden.

Β 

Following a three-pillar strategy, Chesnara's primary responsibility is the efficient administration of its customers' life and savings policies, ensuring good customer outcomes and providing a secure and compliant environment to protect policyholder interests. It also adds value by writing profitable new business in the UK, Sweden and the Netherlands and by undertaking value-adding acquisitions of either companies or portfolios.

Β 

Consistent delivery of the Company strategy has enabled Chesnara to increase its dividend for 20 years in succession.

Β 

Further details are available on the Company's website (www.chesnara.co.uk).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHPPUWCCUPAGMW
Date   Source Headline
1st Jun 20267:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
29th May 20267:00 amRNSDirector/PDMR Shareholding
27th May 20267:00 amRNSDirector/PDMR Shareholding
19th May 20267:00 amRNSDirector/PDMR Shareholding
14th May 20267:00 amRNSDirector/PDMR Shareholding
12th May 20262:00 pmRNSResult of AGM
1st May 20267:00 amRNSTotal Voting Rights
28th Apr 20267:00 amRNSDirector/PDMR Shareholding
17th Apr 20267:00 amRNSAdmission to Trading
10th Apr 20267:00 amRNSHolding(s) in Company
9th Apr 20267:00 amRNSNotice of AGM
1st Apr 20267:00 amRNSTotal Voting Rights
31st Mar 20267:00 amRNSDirector/PDMR Shareholding
27th Mar 20263:40 pmRNSDirector/PDMR Shareholding
27th Mar 20267:00 amRNSDirector/PDMR Shareholding
26th Mar 20267:00 amRNSDirector/PDMR Shareholding
24th Mar 20267:00 amRNSFinal Results
3rd Mar 20267:00 amRNSTotal Voting Rights
2nd Mar 20267:00 amRNSHolding(s) in Company
27th Feb 20267:00 amRNSUpdated Financial Framework and Notice of Results
17th Feb 20267:00 amRNSAcquisition
2nd Feb 20267:00 amRNSCompletion of HSBC Life (UK) Limited Acquisition
30th Jan 20262:00 pmRNSTotal Voting Rights
31st Dec 20257:00 amRNSTotal Voting Rights
31st Dec 20257:00 amRNSTotal Voting Rights
12th Dec 20251:45 pmRNSRegulatory Approval
12th Dec 20257:00 amRNSChange of Registered Office
9th Dec 20257:00 amRNSHolding(s) in Company
2nd Dec 20257:00 amRNSHolding(s) in Company
7th Nov 20257:00 amRNSTotal Voting Rights
30th Oct 20257:00 amRNSHolding(s) in Company
28th Oct 20257:00 amRNSBlock listing Interim Review
27th Oct 202512:04 pmRNSDirector/PDMR Shareholding
6th Oct 20257:00 amRNSTotal Voting Rights
28th Aug 20257:00 amRNSHalf-year Report
14th Aug 20257:00 amRNSNotice of Interim Results
13th Aug 20256:00 pmRNSPrimary Health Properties
30th Jul 20257:00 amRNS£150 MILLION RESTRICTED TIER 1 BOND ISSUE
28th Jul 20257:00 amRNSDirector/PDMR Shareholding
23rd Jul 202510:52 amRNSResult of Rump Placing
23rd Jul 20258:15 amRNSDirector/PDMR Shareholding
23rd Jul 20257:00 amRNSAnnouncement re: Rights Issue
8th Jul 20257:00 amRNSAdmission of Nil Paid Rights
3rd Jul 202512:10 pmRNSPublication of a Prospectus
3rd Jul 20257:00 amRNSAcquisition & Rights Issue
1st Jul 20257:00 amRNSTotal Voting Rights
17th Jun 20257:00 amRNSDirector/PDMR Shareholding
10th Jun 20257:00 amRNSDirector/PDMR Shareholding
6th Jun 20257:00 amRNSDirectorate Change
23rd May 20257:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.